DE69828287T2 - Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen - Google Patents

Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen Download PDF

Info

Publication number
DE69828287T2
DE69828287T2 DE69828287T DE69828287T DE69828287T2 DE 69828287 T2 DE69828287 T2 DE 69828287T2 DE 69828287 T DE69828287 T DE 69828287T DE 69828287 T DE69828287 T DE 69828287T DE 69828287 T2 DE69828287 T2 DE 69828287T2
Authority
DE
Germany
Prior art keywords
peptide
solid phase
terminus
terminal
unprotected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69828287T
Other languages
German (de)
English (en)
Other versions
DE69828287D1 (de
Inventor
Lynne Canne
B. Stephen KENT
Reyna Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Application granted granted Critical
Publication of DE69828287D1 publication Critical patent/DE69828287D1/de
Publication of DE69828287T2 publication Critical patent/DE69828287T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
DE69828287T 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen Expired - Fee Related DE69828287T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
US49553P 1997-06-13
PCT/US1998/012278 WO1998056807A1 (en) 1997-06-13 1998-06-12 Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution

Publications (2)

Publication Number Publication Date
DE69828287D1 DE69828287D1 (de) 2005-01-27
DE69828287T2 true DE69828287T2 (de) 2005-12-15

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
DE69837170T Expired - Fee Related DE69837170T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69837170T Expired - Fee Related DE69837170T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (https=)
EP (1) EP1001968B1 (https=)
JP (1) JP2002505672A (https=)
AT (2) ATE354584T1 (https=)
AU (1) AU745094B2 (https=)
CA (1) CA2292724A1 (https=)
DE (2) DE69828287T2 (https=)
ES (2) ES2282788T3 (https=)
WO (1) WO1998056807A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
AU745094B2 (en) * 1997-06-13 2002-03-14 Gryphon Sciences Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution
WO1999011655A1 (en) * 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
EP1159289A1 (en) * 1999-03-11 2001-12-05 Gryphon Sciences Chemical synthesis and use of soluble membrane protein receptor domains
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
JP2004506221A (ja) * 2000-08-11 2004-02-26 インヴィトロジェン　コーポレーション 高度に均一な電気泳動用分子マーカー
KR20030046389A (ko) * 2000-09-01 2003-06-12 그리폰 테라퓨틱스, 인코포레이티드 친핵체에 안정한 티오에스테르 발생 화합물, 제조 및 사용방법
WO2002057293A2 (en) * 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US7256275B2 (en) * 2001-03-09 2007-08-14 Boston Probes, Inc. Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7781488B2 (en) * 2002-06-10 2010-08-24 Amylin Pharmaceuticals, Inc. Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
JP2005531616A (ja) * 2002-06-29 2005-10-20 アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング イソフラボン濃縮物およびその製造法
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US20040198958A1 (en) * 2002-12-11 2004-10-07 Ming-Qun Xu Carrier-ligand fusions and uses thereof
EP1616003A4 (en) 2002-12-30 2007-06-20 Gryphon Therapeutics Inc WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) * 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
WO2004105685A2 (en) * 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
JP4895826B2 (ja) * 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成蛋白−２の正のモジュレーター
TWI351284B (en) 2004-04-09 2011-11-01 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs
US7872096B2 (en) * 2004-05-24 2011-01-18 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
CN102343084A (zh) 2005-03-31 2012-02-08 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007100358A2 (en) * 2005-10-07 2007-09-07 University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
JP2009541358A (ja) 2006-06-22 2009-11-26 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成を強化するためにｂｍｐ−２増幅因子／共活性化因子を送達するための組成物および方法
US8309522B2 (en) 2007-02-05 2012-11-13 Amylin Pharmaceuticals, Llc Neuromedin and FN-38 peptides for treating psychiatric diseases
US8404804B2 (en) * 2007-08-28 2013-03-26 Ipsen Pharma S.A.S. Methods and intermediates for chemical synthesis of polypeptides and proteins
EP2536287A4 (en) * 2010-02-18 2015-10-07 Advanced Proteome Therapeutics Inc SPECIFIC SITE SIZE OF PROTEINS USING CHEMICAL MODIFICATION TO PROMOTE PROTEIN CONJUGATE FORMATION, PROTEIN DIMER FORMATION, AND AGRAFTED PEPTIDES
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
CA2873112A1 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
CN110382516B (zh) * 2017-03-02 2022-11-08 株式会社糖锁工学研究所 氨基酸聚合物的制备方法
WO2020070587A1 (en) 2018-10-01 2020-04-09 Université De Genève Methods for producing a plurality of polypeptide variants suitable for biological analysis
WO2020110330A1 (ja) * 2018-11-30 2020-06-04 株式会社糖鎖工学研究所 ペプチドチオエステル、ペプチドの新規製造方法
WO2021072306A1 (en) 2019-10-10 2021-04-15 1859, Inc. Methods and systems for microfluidic screening
WO2021077317A1 (zh) * 2019-10-23 2021-04-29 烟台迈百瑞国际生物医药股份有限公司 一种寡肽连接子中间体及其制备方法
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DK0832096T3 (da) 1995-05-04 2001-10-01 Scripps Research Inst Syntese af proteiner ved nativ kemisk ligering
WO1998028434A1 (en) 1996-12-24 1998-07-02 The Scripps Research Institute General chemical ligation
AU745094B2 (en) * 1997-06-13 2002-03-14 Gryphon Sciences Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
US7094871B2 (en) 2006-08-22
DE69837170D1 (de) 2007-04-05
ATE285415T1 (de) 2005-01-15
US20020132975A1 (en) 2002-09-19
CA2292724A1 (en) 1998-12-17
AU8069598A (en) 1998-12-30
ES2235336T3 (es) 2005-07-01
JP2002505672A (ja) 2002-02-19
ATE354584T1 (de) 2007-03-15
AU745094B2 (en) 2002-03-14
DE69828287D1 (de) 2005-01-27
WO1998056807A1 (en) 1998-12-17
US20050209440A1 (en) 2005-09-22
EP1001968B1 (en) 2004-12-22
EP1001968A1 (en) 2000-05-24
US7030217B2 (en) 2006-04-18
ES2282788T3 (es) 2007-10-16
US6326468B1 (en) 2001-12-04
DE69837170T2 (de) 2007-11-22
US20020169282A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DE69828287T2 (de) Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
EP0285562B1 (de) Kunstharz
DE69430312T2 (de) Peralkylierte oligopeptidmischungen
Bodanszky et al. Synthesis of secretin. I. The protected tetradecapeptide corresponding to sequence 14-27
DE60208684T2 (de) Verbesserte native chemische ligation mit drei oder mehreren komponenten
CA2273071C (en) Method for ligating oligopeptides
DE2540780A1 (de) Verfahren zum herstellen von peptiden mit einer disulfidringstruktur
DE2717741A1 (de) Synthetisches antigen-wirksames polypeptid
JP2002525376A (ja) アミド結合形成のための補助基
BRPI0202783B1 (pt) processo para a síntese rápida de um peptídeo em solução em um solvente orgânico ou em uma mistura de solventes orgânicos, e, métodos para a síntese combinatória de coleções de peptídeo e para a síntese de peptídeo automatizada em solução
DE2923787A1 (de) Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
DE69325987T2 (de) Verfahren zur Herstellung von Lachs-Calcitonin
DE69604759T2 (de) N alpha-2-(4-nitrophenylsulfonyl)ethoxycarbonyl-aminosäuren
EP0051205B1 (de) Neues Tridekapeptid, Verfahren zu seiner Herstellung und Verwendung
DE69218193T2 (de) Verfahren zur Synthese von Peptiden, Derivate von Aminosäuren zur Verwendung bei dem obengenannten Verfahren und Methoden zu deren Herstellung.
DE60303314T2 (de) Verfahren zum carboxygruppenschutz der säuren c-terminalen aminosäuren bei chemischer verknüpfung von oligopeptiden
DE2830442C2 (https=)
DE2505712A1 (de) Traegergebundene sowie biologisch aktive peptide und herstellungsverfahren dafuer
EP1518862B1 (en) Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
Sucholeiki et al. An affinity chromatographic method for the purification of water-insoluble peptides
HU185238B (en) Process for preparing peptides containing guanidino-group
CH645880A5 (de) Synthetisches antigenaktives polypeptid, verfahren zu dessen herstellung und das polypeptid enthaltendes antigenes mittel sowie arzneimittel.
DE2703121A1 (de) Synthetische pentapeptide und sie enthaltende arzneimittel
EP4622989A1 (en) Method of preparing vasopressin
DE69102659T2 (de) Synthese von LH-RH-Analogen unter Anwendung eines zeitlich begrenzten minimalen Schutzes.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMYLIN PHARMACEUTICALS, INC. (N.D.GES.D. STAAT, US

8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT

8339 Ceased/non-payment of the annual fee